The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling

Conclusions: Our findings suggest that iNOS inhibition is a promising cardioprotective strategy to accompany HER2-inhibitor/anthracycline combination therapies. Furthermore, these results support the promise of hPSC-CMs as a platform for investigating cardiotoxicity and developing cardioprotectants as a whole.

Source: Theranostics - June 20, 2018 Category: Molecular Biology Authors: Wan-Tseng Hsu, Ching-Ying Huang, Christopher Y.T. Yen, Ann-Lii Cheng, Patrick C.H. Hsieh Tags: Research Paper Source Type: research